[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Contempo Updates
November 14, 2001

Clinical ProteomicsPersonalized Molecular Medicine

Author Affiliations

Author Affiliations: National Cancer Institute, CCR, National Institutes of Health, Bethesda, Md (Drs Liotta and Kohn); and Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Md (Dr Petricoin).

 

Contempo Updates Section Editor: Janet M. Torpy, MD, Fishbein Fellow.

JAMA. 2001;286(18):2211-2214. doi:10.1001/jama.286.18.2211

The cause of most human disease lies in the functional dysregulation of protein interactions. Proteomics, which includes the study of cellular protein interactions, has evolved from advances in scientific knowledge and technology. Understanding the role that protein networks play in disease will create enormous clinical opportunities, because these pathways represent the drug targets of the next decade. In the future, entire cellular networks, not just one dysregulated protein, will be the target of therapeutics. The next technologic leap will be the application of proteomic technologies to the bedside. Soon it will be possible to analyze the state of protein signal pathways in the disease-altered cells before, during, and after therapy, heralding the advent of true patient-tailored therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×